The global monoclonal antibodies in veterinary health market size was US$ 671.6 million in 2021. The global monoclonal antibodies in veterinary health market are expected to grow to US$ 2371.1 million by 2030 by registering a compound annual growth rate (CAGR) of 17.1% during the forecast period from 2022 to 2030.

Factors Influencing the Market
The rising rate of pet adoption, combined with the increasing demand for better companion animal treatment choices, will fuel the growth of monoclonal antibodies in the veterinary health market during the analysis period. Additionally, the market is also driven by the rising cost of pets, increasing demand for effective therapies, and growing cases of allergies in pets.
The demand for monoclonal antibodies in veterinary health will increase due to the rising knowledge about the significance of therapeutic monoclonal antibodies and pet insurance. Other factors, like pet health initiatives taken by the government and private organizations, will contribute to the growth of monoclonal antibodies in the veterinary health market during the analysis period.
Growing incidences of cancer, majorly in dogs, will drive the demand for monoclonal antibodies in veterinary health during the analysis period. The American Veterinary Medical Association reports that 1 in 4 dogs suffer from neoplasia at some point, which increases the need for efficient healthcare treatment.

Regional Analysis
North America garnered the largest share the monoclonal antibodies in the veterinary health market due to the growing contribution of the government and corporate sector and the rising popularity of pet insurance. Additionally, the high adoption of pets in the region is expected to present attractive prospects for the growth of monoclonal antibodies in the veterinary health market.
The Asia-Pacific monoclonal antibodies in the veterinary health market are expected to develop at a significant growth rate due to the rising number of local competitors and veterinary hospitals and clinics. Further, the growing adoption of pets, combined with the rising knowledge about the early precautions to protect the pet from illnesses, will drive the monoclonal antibodies in the veterinary health market forward during the analysis period.

COVID-19 Impact Analysis
Animal health was given less priority during the COVID-19 pandemic as the COVID-19 infection is a contagious virus, and there were high chances of virus transmission from the patients. Therefore, the demand for monoclonal antibodies in veterinary health decreased dramatically. Moreover, visits to healthcare professionals for pets also decreased, and various clinics closed their doors in order to abide by the government's restrictions. As a result, it impeded the growth of monoclonal antibodies in the veterinary health market for a prolonged period.

Competitors in the Market
Adivo GmbH
Bayer Animal Health
Boehringer Ingelheim GmbH
Elanco
Indian Immunologicals Ltd.
Invetx
Kindred Biosciences, Inc.
Merck & Co. Inc
Nextmune
Virbac
Zoetis
Other Prominent Players

Market Segmentation
The global monoclonal antibodies in veterinary health market segmentation focus on Animal, Application, End-Use, and Region.
By Animal Type
Dogs
Others
By Application
Dermatology
Pain
Others
By End-Use
Veterinary Hospitals
Others
By Region
North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
UAE
Saudi Arabia
South Africa
Rest of MEA
South America
Brazil
Argentina
Rest of South America